Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PCR Enzyme Patent Dispute Leads To Overbilling Charges; DoJ Takes A Pass

This article was originally published in The Gray Sheet

Executive Summary

The Department of Justice says it will not intervene in a Promega civil action alleging that Roche overbilled the government for Taq enzyme-related products, and seeking redress under the False Claims Act

You may also be interested in...



Roche v. Promega split decision

Roche is preparing litigation against Promega for infringing its polymerase chain reaction patents, following a 1San Francisco District Court ruling that failed to substantiate Promega's assertion that Roche's '195 and '202 patents are unenforceable. Meanwhile, Promega applauds the court's dismissal of Roche's '818 Taq enzyme patent claims based on a finding of "inequitable conduct." Roche will appeal the Taq ruling, although the firm notes that several other enzymes can facilitate PCR. Promega will take advantage of an invitation from Judge Vaughn Walker to submit additional evidence before he makes a final ruling on the '195 and '202 patents. Litigation surrounding the Taq patent has continued for over a decade. Most recently, Promega revealed a lawsuit alleging False Claims Act violations in Eastern Virginia District Court (2"The Gray Sheet" Nov. 17, 2003, p. 10)...

Roche v. Promega split decision

Roche is preparing litigation against Promega for infringing its polymerase chain reaction patents, following a 1San Francisco District Court ruling that failed to substantiate Promega's assertion that Roche's '195 and '202 patents are unenforceable. Meanwhile, Promega applauds the court's dismissal of Roche's '818 Taq enzyme patent claims based on a finding of "inequitable conduct." Roche will appeal the Taq ruling, although the firm notes that several other enzymes can facilitate PCR. Promega will take advantage of an invitation from Judge Vaughn Walker to submit additional evidence before he makes a final ruling on the '195 and '202 patents. Litigation surrounding the Taq patent has continued for over a decade. Most recently, Promega revealed a lawsuit alleging False Claims Act violations in Eastern Virginia District Court (2"The Gray Sheet" Nov. 17, 2003, p. 10)...

Roche To Appeal Native Taq Ruling To Defend Scientific Integrity

Roche Molecular Systems and parent company Hoffman-La Roche intend to appeal a Dec. 7 San Francisco federal district court ruling that the firm's native Taq polymerase patent is "unenforceable" because of inequitable conduct during Cetus Corp.' s patent application process in 1986, Roche said Dec. 8.

Related Content

UsernamePublicRestriction

Register

MT019341

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel